Biosite® Inc. Web Site -- Triage® BNP Test

By: Alere  09-12-2011

The Triage® BNP Test  

    A rapid, objective point-of-care immunoassay used:
    • as an aid in the diagnosis of CHF
    • as an aid in the assessment of severity of CHF
    • for the risk stratification of patients with ACS
    • for the risk stratification of patients with HF
    This test is CLIA waived for use with whole-blood samples.

The Triage® BNP Test is the first objective measurement for heart failure.

  • The only CLIA waived blood test measuring B-type natriuretic peptide (BNP)
  • Cardiac hormone produced by the heart ventricles in response to ventricular volume expansion and pressure overload1
  • Excellent hormonal marker of ventricular systolic and diastolic dysfunction2

The Triage® BNP Test provides meaningful diagnostic information:

  • 98 percent diagnostic accuracy in initial studies versus all other clinical findings in patients with or without disease history3
  • Quantitative and accurate, rapid results help differentiate nonspecific signs and symptoms (dyspnea)3 with results in approximately 15 minutes
  • 98 percent specificity using a 100 pg/mL cutoff4
  • >98 percent negative predictive value utilizing 100 pg/mL cutoff*4
  • Corrected 96 percent of misdiagnoses of patients with suspected heart failure in initial studies3
  • Diagnostic accuracy confirmed for:
    • Early- and late-stage heart failure in point-of-care setting3
    • Patients with normal and abnormal ejection fractions4
  • Studies indicate that BNP is predictive of systolic and diastolic left ventricular dysfunction3
  • BNP levels are not influenced by hypertension, diabetes, renal insufficiency, or chronic obstructive pulmonary disease4

* The Triage BNP Test is intended for use with the Triage Meters for the rapid in vitro quantitative measurement of B-Type Natriuretic Peptide (BNP) in human whole-blood or plasma specimens using EDTA as the anticoagulant.

†Negative predictive value (NPV) was calculated to reflect the incidence of heart failure, according to data from the American Heart Association 2000 Heart and Stroke Statistical Update and Health, United States, 2000 (National Center for Health Statistics).

See Triage BNP Test Product Insert for full information


Other products and services from Alere

09-12-2011

Biosite® Inc. Web Site -- Cardiac Panel

Finally, technology that has caught up with your needs.Rapid, quantitative measurement of CK-MB, myoglobin, and troponin I to aid in the diagnosis of acute myocardial infarction. Rapid, actionable information to aid in the diagnosis of acute myocardial infarction. Enables triage decisions in under two hours when used with accelerated protocol 1. Simultaneous cardiac marker results from whole blood in approximately 15 minutes.


09-12-2011

Biosite® Inc. Web Site -- D-Dimer Test

A rapid, quantitative immunoassay to aid in the assessment and evaluation of patients suspected of having disseminated intravascular coagulation and thromboembolic events including pulmonary embolism and deep vein thrombosis. Performed on the Triage Meters.


09-12-2011

Biosite® Inc. Web Site -- Products

Through combined expertise in diagnostic discovery and commercialization, Biosite is focused on developing novel diagnostics tests that are capable of immediately and accurately diagnosing and assessing critical conditions, which can take several hours or even days using conventional testing methods.


09-12-2011

Biosite® Inc. Web Site -- Profiler Shortness of Breath

The Triage® Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment of patients with acute coronary syndromes. Troponin I, CK-MB, myoglobin, BNP and D-dimer each provide unique clinical information, and the panel approach maximizes the strengths of each marker.


09-12-2011

Biosite® Inc. Web Site -- TOX Drug Screen -- TOX Drug Screen

According to the National Academy of Clinical Biochemistry, Laboratory Medicine Practice Guidelines, stat toxicology assays required to support an ED should have a turnaround time of one hour or less. The Value of Point-of-Care Drug Testing Nearly every day patients are treated in emergency departments across the country for complications due to drug overdose.


09-12-2011

Biosite® Inc. Web Site -- Triage System

An immunoassay for use as an aid in the diagnosis of acute myocardial infarction, the diagnosis and assessment of severity of congestive heart failure, and the risk stratification of patients with acute coronary syndromes and congestive heart failure. An immunoassay for the quantitative determination of CK-MB, myoglobin, and troponin I in whole blood or plasma, as an aid in the diagnosis of acute myocardial infarction.